Hepatoprotective effect of the endothelin receptor antagonist TAK-044 against ischemia-reperfusion injury in the canine liver

Hepatology

Volumn 25, Issue 4, 1997, Pages 938-942

  Kitayama, Yoshihiro ^a   Yamanaka, Naoki ^a   Kawamura, Eisuke ^a   Kuroda, Nobukazu ^a   Okamoto, Eizo ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; INDOCYANINE GREEN; LIVER PROTECTIVE AGENT; TAK 044;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; HISTOPATHOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LIVER INJURY; LIVER ISCHEMIA; LIVER PROTECTION; MALE; MICROCIRCULATION; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; DOGS; ENDOTHELIN-1; LIVER; LIVER CIRCULATION; MALE; PEPTIDES, CYCLIC; RECEPTORS, ENDOTHELIN; REPERFUSION INJURY;

EID: 0030940325     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510250425     Document Type: Article

References (23)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
2. Goto M, Takei Y, Kawano S, Nagano K, Tsuji S, Masuda E, Nishimura Y, et al. Endothelin-1 is involved in the pathogenesis of ischemia/reperfusion liver injury by hepatic microcirculatory disturbances. HEPATOLOGY 1994; 19:675-681.
3. Okumura S, Takei Y, Kawano S, Nagano K, Masuda E, Goto M, Tsuji S, et al. Vasoactive effect of endothelin-1 on rat liver in vivo. HEPATOLOGY 1994;19:155-161.
4. Tran-Thi T, Kawada N, Decker K. Regulation of endothelin-1 action on the perfused rat liver. FEES Lett 1993;318:353-357.
5. Gandhi CR, Behal RH, Harvey SAK, Nouchi TA, Olson MS. Hepatic effects of endothelin. Biochem J 1992;287:897-904.
6. Kawamura E, Yamanaka N, Okamoto E, Tomoda F, Furukawa K. Response of plasma and tissue endothelin-1 to liver ischemia and its implication in ischemia-reperfusion injury. HEPATOLOGY 1995;21:1138-1143.
7. A) antagonist isolated from Streptomyces misakiensis. Biochem Biophys Res Commun 1991;178:132-137.
8. Ihara M, Noguchi K, Saeki T, Fukuroda T, Tuchida S, Kimura S, Fukami T, et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 1992;50:247-255.
9. Sogabe K, Nirei H, Shoubo M, Nomoto A, Ao S, Notsu Y, Ono T. Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist. J Pharmacol Exp Ther 1993;264:1040-1046.
10. 15]-endothelin-l(11-21). FEBS Lett 1992;311:12-16.
11. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, Fukuroda T, et al. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A 1994; 91:4892-4896.
12. Tanaka T, Tsukuda E, Nozawa M, Nonaka H, Ohono T, Kase H, Yamada K, et al. RES-701-1, a novel, potent, endothelin type B receptor-selective antagonist of microbial origin. Mol Pharmacol 1994;45:724-730.
13. Clozel M, Gray GA, Breu V, Loffler BM, Osterwalder R. The endothelin ETB receptor mediates both vasodilatation and vasoconstriction in vivo. Biochem Biophys Res Commun 1992;186:867-873.
14. Memurdo L, Corder R, Triemermann C, Vane JR. Incomplete inhibition of the pressor effects of endothelin-1 and related peptides in the anaesthetized rat with BQ-123 provides evidence for more than one vasoconstrictor receptor. Br J Pharmacol 1993; 108:557-561.
15. Kiso T, Ito S, Ohta T, Asano T, Nakazato Y. Characterization of vasoactive intestinal peptide receptors in canine liver membrane. Biochem Pharmacol 1994;47:241-245.
16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. Biol Chem 1951;193:265-273.
17. Ikeda S, Oka JI, Nagao T. Effect of four diltiazem stereoisomers on binding of d-cis-[3H] diltiazem and (+)-[3H] PN-200-110 to rabbit T-tubule calcium channels. Eur J Pharmacol 1991;208:199-205.
18. Weibel ER, Kistler GS, Scherle WF. Practical stereological methods for morphometric cytology. J Cell Biol 1966;30:23-38.
19. Masaki T. Reduced sensitivity of vascular response to endothelin. Circulation 1993;87(suppl V):V33-V35.
20. Gandhi CR, Stephenson K, Olson MS. Endothelin, a potent peptide agonist in the liver. J Biol Chem 1990;265:17432-17435.
21. B mediated blood pressure responses in rats. J Pharmacol Exp Ther 1994;270:728-733.
22. Ohlstein EH, Nambi P, Douglas SA, Edwards RM, Gellai M, Lago A, Leber JD, et al. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci U S A 1994;91:8052-8056.
23. Clozel M, Breu V, Gray GA, Kalina B, Lofiler B-M, Burri K, Cassai J-M, et al. Pharmacological characterization of Bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270:228-235.